Protalix (PLX) Q2 2026 Earnings Call Transcript
Protalix (PLX) reported Q2 2026 revenues of $19.9M, up from $15.7M in Q2 2025, driven by higher sales to Chiesi. Net income was $3.8M, or $0.05 per share. The company expects top-line results from its RELEASE study in late 2027 and remains focused on rare renal diseases. Cash reserves totaled $40.7M as of June 30, 2026.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh financial metrics and confirms progress on key partnerships, offering a clearer view of near‑term valuation.
Market read
The Q2 2026 earnings provide material new data for investors, potentially influencing PLX stock and related biotech peers.
What to watch
Future revenue hinges on the RELEASE study results in 2027 and partnership dynamics with Chiesi and Pfizer.
Background
Protalix is a biopharmaceutical company focused on rare renal diseases and uricase therapies.
Ticker impact
Q2 2026 earnings released with revenue $19.9M, net income $3.8M and guidance indicating continued growth.
Potential short-term price rally as investors digest stronger-than-expected results.
The company reported a 27% YoY revenue increase and turned profitable, which is material new information for a small‑cap biotech.
Market effects
Positive earnings may lift peer rare‑disease biotech stocks and highlight demand for uricase therapies.
Limited to US‑listed biotech sector; no broader regional effect.
Modest, confined to niche biotech investors.
Counterpoint
Despite earnings beat, the company remains cash‑flow limited and dependent on upcoming trial data, which could temper upside.
Key entities
- CompanyProtalix
Issuer of the earnings report.
- ExecutiveGilad Mamlok
Presented the financial results.
- ExecutiveDror Bashan
Provided commentary on pipeline and outlook.
